Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Myelofibrosis with Thrombocytopenia
NCT07394153Phase 2Recruiting
- Sponsor
- GEMFIN
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in myelofibrosis (MF), sponsored by GEMFIN. Started Apr 2026; status: recruiting.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07394153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394153.